Immune and inflammatory cell composition of human lung cancer stroma

PLoS ONE

Volumn 10, Issue 9, 2015, Pages

  Banat, G Andre ^a   Tretyn, Aleksandra ^b   Pullamsetti, Soni Savai ^a,b   Wilhelm, Jochen ^a   Weigert, Andreas ^c   Olesch, Catherine ^c   Ebel, Katharina ^b   Stiewe, Thorsten ^d   Grimminger, Friedrich ^a   Seeger, Werner ^a,b   Fink, Ludger ^e   Savai, Rajkumar ^a,b  

^a JUSTUS LIEBIG UNIVERSITY   (Germany)

^b MAX PLANCK INSTITUTE FOR HEART AND LUNG RESEARCH   (Germany)

^c GOETHE UNIVERSITY   (Germany)

^d PHILIPPS UNIVERSITY MARBURG   (Germany)

^e Institute of Pathology and Cytology   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CD20 ANTIGEN; CD3 ANTIGEN; CD4 ANTIGEN; CD68 ANTIGEN; CD8 ANTIGEN; CELL MARKER; GLYCOPROTEIN P 15095; INTERFERON REGULATORY FACTOR 4; MYELOPEROXIDASE; PROGRAMMED DEATH 1 RECEPTOR; STEM CELL FACTOR RECEPTOR; LEUKOCYTE ANTIGEN; PEROXIDASE;

ADENOSQUAMOUS CARCINOMA; ARTICLE; B LYMPHOCYTE; BONE MARROW CELL; CANCER INFILTRATION; CANCER STAGING; CELL COMPOSITION; CELL INFILTRATION; CONTROLLED STUDY; CYTOCHEMISTRY; CYTOTOXIC T LYMPHOCYTE; HELPER CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOCOMPETENT CELL; IMMUNOHISTOCHEMISTRY; INFLAMMATORY CELL; LUNG ADENOCARCINOMA; LUNG ALVEOLUS CELL CARCINOMA; LUNG CANCER; LUNG CARCINOGENESIS; LYMPHOCYTIC INFILTRATION; MACROPHAGE; MAJOR CLINICAL STUDY; MAST CELL; MONONUCLEAR CELL; NEUTROPHIL; PLASMA CELL; SMALL CELL LUNG CANCER; SQUAMOUS CELL LUNG CARCINOMA; STROMA CELL; T LYMPHOCYTE ACTIVATION; TISSUE MICROARRAY; TUMOR CLASSIFICATION; TUMOR MICROENVIRONMENT; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; IMMUNOLOGY; INFLAMMATION; LUNG TUMOR; METABOLISM; PATHOLOGY;

ANTIGENS, CD; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; HUMANS; IMMUNOHISTOCHEMISTRY; INFLAMMATION; LUNG NEOPLASMS; PEROXIDASE; STROMAL CELLS; TUMOR MICROENVIRONMENT;

EID: 84946944615     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0139073     Document Type: Article

References (42)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013; 63(1):11-30. doi: 10.3322/caac.21166 PMID: 23335087.
2. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA: a cancer journal for clinicians. 2011; 61(2):69-90. Epub 2011/02/08. doi: 10.3322/caac.20107 PMID: 21296855.
3. Nana-Sinkam SP, Powell CA. Molecular biology of lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013; 143(5 Suppl):e30S-9S. Epub 2013/05/10. doi: 10.1378/chest.12-2346 PMID: 23649444; PubMed Central PMCID: PMC3961820.
4. Lorenz J, Friedberg T, Paulus R, Oesch F, Ferlinz R. Oncogene overexpression in non-small-cell lung cancer tissue: prevalence and clinicopathological significance. Clin Investig. 1994; 72(2):156-63. PMID: 8186664.
5. Peifer M, Fernandez-Cuesta L, Sos ML, George J, Seidel D, Kasper LH, et al. Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. Nat Genet. 2012; 44(10):1104-10. doi: 10.1038/ng.2396 PMID: 22941188.
6. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011; 144(5):646-74. Epub 2011/03/08. doi: 10.1016/j.cell.2011.02.013 PMID: 21376230.
7. Swartz MA, Iida N, Roberts EW, Sangaletti S, Wong MH, Yull FE, et al. Tumor microenvironment complexity: emerging roles in cancer therapy. Cancer Res. 2012; 72(10):2473-80. Epub 2012/03/15. doi: 10.1158/0008-5472.CAN-12-0122 PMID: 22414581; PubMed Central PMCID: PMC3653596.
8. Hanahan D, Coussens LM. Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer cell. 2012; 21(3):309-22. Epub 2012/03/24. doi: 10.1016/j.ccr.2012.02.022 PMID: 22439926.
9. Remark R, Becker C, Gomez JE, Damotte D, Dieu-Nosjean MC, Sautes-Fridman C, et al. The nonsmall cell lung cancer immune contexture. A major determinant of tumor characteristics and patient outcome. Am J Respir Crit Care Med. 2015; 191(4):377-90. Epub 2014/11/05. doi: 10.1164/rccm.201409- 1671PP PMID: 25369536.
10. Bindea G, Mlecnik B, Tosolini M, Kirilovsky A, Waldner M, Obenauf AC, et al. Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. Immunity. 2013; 39 (4):782-95. Epub 2013/10/22. doi: 10.1016/j.immuni.2013.10.003 PMID: 24138885.
11. Murdoch C, Muthana M, Coffelt SB, Lewis CE. The role of myeloid cells in the promotion of tumour angiogenesis. Nature reviews Cancer. 2008; 8(8):618-31. Epub 2008/07/18. doi: 10.1038/nrc2444 PMID: 18633355.
12. Schmall A, Al-Tamari HM, Herold S, Kampschulte M, Weigert A, Wietelmann A, et al. Macrophage and cancer cell cross-talk via CCR2 and CX3CR1 is a fundamental mechanism driving lung cancer. Am J Respir Crit Care Med. 2015; 191(4):437-47. Epub 2014/12/24. doi: 10.1164/rccm.201406-1137OC PMID: 25536148.
13. El-Nikhely N, Larzabal L, Seeger W, Calvo A, Savai R. Tumor-stromal interactions in lung cancer: novel candidate targets for therapeutic intervention. Expert Opin Investig Drugs. 2012; 21(8):1107-22. doi: 10.1517/13543784.2012.693478 PMID: 22667993.
14. Tartour E, Zitvogel L. Lung cancer: potential targets for immunotherapy. The Lancet Respiratory medicine. 2013; 1(7):551-63. Epub 2014/01/28. doi: 10.1016/S2213-2600(13)70159-0 PMID: 24461616.
15. Kataki A, Scheid P, Piet M, Marie B, Martinet N, Martinet Y, et al. Tumor infiltrating lymphocytes and macrophages have a potential dual role in lung cancer by supporting both host-defense and tumor progression. J Lab Clin Med. 2002; 140(5):320-8. doi: 10.1067/mlc.2002.128317 PMID: 12434133.
16. Ruffini E, Asioli S, Filosso PL, Lyberis P, Bruna MC, Macri L, et al. Clinical significance of tumor-infiltrating lymphocytes in lung neoplasms. Ann Thorac Surg. 2009; 87(2):365-71; discussion 71-2. doi:10. 1016/j.athoracsur.2008.10.067 PMID: 19161739.
17. Kawai O, Ishii G, Kubota K, Murata Y, Naito Y, Mizuno T, et al. Predominant infiltration of macrophages and CD8(+) T Cells in cancer nests is a significant predictor of survival in stage IV nonsmall cell lung cancer. Cancer. 2008; 113(6):1387-95. doi: 10.1002/cncr.23712 PMID: 18671239.
18. Kilic A, Landreneau RJ, Luketich JD, Pennathur A, Schuchert MJ. Density of tumor-infiltrating lymphocytes correlates with disease recurrence and survival in patients with large non-small-cell lung cancer tumors. J Surg Res. 2011; 167(2):207-10. doi: 10.1016/j.jss.2009.08.029 PMID: 19896677.
19. Al-Shibli KI, Donnem T, Al-Saad S, Persson M, Bremnes RM, Busund LT. Prognostic effect of epithelial and stromal lymphocyte infiltration in non-small cell lung cancer. Clin Cancer Res. 2008; 14(16):5220-7. doi: 10.1158/1078-0432.CCR-08-0133 PMID: 18698040.
20. Savai R, Pullamsetti SS, Kolbe J, Bieniek E, Voswinckel R, Fink L, et al. Immune and inflammatory cell involvement in the pathology of idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med. 2012; 186(9):897-908. doi: 10.1164/rccm.201202-0335OC PMID: 22955318.
21. Savai R, Al-Tamari HM, Sedding D, Kojonazarov B, Muecke C, Teske R, et al. Pro-proliferative and inflammatory signaling converge on FoxO1 transcription factor in pulmonary hypertension. Nat Med. 2014; 20(11):1289-300. Epub 2014/10/27. doi: 10.1038/nm.3695 PMID: 25344740.
22. El Kasmi KC, Pugliese SC, Riddle SR, Poth JM, Anderson AL, Frid MG, et al. Adventitial fibroblasts induce a distinct proinflammatory/profibrotic macrophage phenotype in pulmonary hypertension. J Immunol. 2014; 193(2):597-609. doi: 10.4049/jimmunol.1303048 PMID: 24928992.
23. McCullagh P, Nelder JA. Generalized linear models. 2nd ed. London; New York: Chapman and Hall; 1989. xix, 511 p.
24. Turner H. A peer-reviewed, open-access publication of the R Foundation for Statistical Computing. R Journal. 2011; 3(2):3-. PMID: WOS:000208590200001.
25. Gardner W, Mulvey EP, Shaw EC. Regression analyses of counts and rates: Poisson, overdispersed Poisson, and negative binomial models. Psychological bulletin. 1995; 118(3):392-404. PMID: 7501743.
26. Bremnes RM, Al-Shibli K, Donnem T, Sirera R, Al-Saad S, Andersen S, et al. The role of tumor-infiltrating immune cells and chronic inflammation at the tumor site on cancer development, progression, and prognosis: emphasis on non-small cell lung cancer. J Thorac Oncol. 2011; 6(4):824-33. doi: 10.1097/ JTO.0b013e3182037b76 PMID: 21173711.
27. Prado-Garcia H, Romero-Garcia S, Aguilar-Cazares D, Meneses-Flores M, Lopez-Gonzalez JS. Tumor-induced CD8+ T-cell dysfunction in lung cancer patients. Clin Dev Immunol. 2012; 2012:741741. doi: 10.1155/2012/741741 PMID: 23118782; PubMed Central PMCID: PMC3483679.
28. Welsh TJ, Green RH, Richardson D, Waller DA, O'Byrne KJ, Bradding P. Macrophage and mast-cell invasion of tumor cell islets confers a marked survival advantage in non-small-cell lung cancer. J Clin Oncol. 2005; 23(35):8959-67. doi: 10.1200/JCO.2005.01.4910 PMID: 16219934.
29. Zaynagetdinov R, Sherrill TP, Polosukhin VV, Han W, Ausborn JA, McLoed AG, et al. A critical role for macrophages in promotion of urethane-induced lung carcinogenesis. J Immunol. 2011; 187(11):5703-11. doi: 10.4049/jimmunol.1100558 PMID: 22048774; PubMed Central PMCID: PMC3221921.
30. Chen JJ, Lin YC, Yao PL, Yuan A, Chen HY, Shun CT, et al. Tumor-associated macrophages: the double- edged sword in cancer progression. J Clin Oncol. 2005; 23(5):953-64. doi: 10.1200/JCO.2005.12. 172 PMID: 15598976.
31. Sica A, Mantovani A. Macrophage plasticity and polarization: in vivo veritas. J Clin Invest. 2012; 122 (3):787-95. doi: 10.1172/JCI59643 PMID: 22378047; PubMed Central PMCID: PMC3287223.
32. Ohnuki H, Jiang K, Wang D, Salvucci O, Kwak H, Sanchez-Martin D, et al. Tumor-infiltrating myeloid cells activate Dll4/Notch/TGF-beta signaling to drive malignant progression. Cancer Res. 2014; 74 (7):2038-49. doi: 10.1158/0008-5472.CAN-13-3118 PMID: 24520074; PubMed Central PMCID: PMC3985086.
33. Bellocq A, Antoine M, Flahault A, Philippe C, Crestani B, Bernaudin JF, et al. Neutrophil alveolitis in bronchioloalveolar carcinoma: induction by tumor-derived interleukin-8 and relation to clinical outcome. Am J Pathol. 1998; 152(1):83-92. PMID: 9422526; PubMed Central PMCID: PMC1858104.
34. Hume DA. Macrophages as APC and the dendritic cell myth. J Immunol. 2008; 181(9):5829-35. PMID: 18941170.
35. Perrot I, Blanchard D, Freymond N, Isaac S, Guibert B, Pacheco Y, et al. Dendritic cells infiltrating human non-small cell lung cancer are blocked at immature stage. J Immunol. 2007; 178(5):2763-9. PMID: 17312119.
36. de Visser KE, Korets LV, Coussens LM. De novo carcinogenesis promoted by chronic inflammation is B lymphocyte dependent. Cancer Cell. 2005; 7(5):411-23. doi: 10.1016/j.ccr.2005.04.014 PMID: 15894262.
37. Shapiro-Shelef M, Calame K. Regulation of plasma-cell development. Nat Rev Immunol. 2005; 5 (3):230-42. doi: 10.1038/nri1572 PMID: 15738953.
38. Lohr M, Edlund K, Botling J, Hammad S, Hellwig B, Othman A, et al. The prognostic relevance of tumour-infiltrating plasma cells and immunoglobulin kappa C indicates an important role of the humoral immune response in non-small cell lung cancer. Cancer Lett. 2013; 333(2):222-8. doi: 10.1016/j. canlet.2013.01.036 PMID: 23370224.
39. Fujimoto M, Yoshizawa A, Sumiyoshi S, Sonobe M, Kobayashi M, Koyanagi I, et al. Stromal plasma cells expressing immunoglobulin G4 subclass in non-small cell lung cancer. Hum Pathol. 2013; 44 (8):1569-76. doi: 10.1016/j.humpath.2013.01.002 PMID: 23465276.
40. Francisco LM, Sage PT, Sharpe AH. The PD-1 pathway in tolerance and autoimmunity. Immunol Rev. 2010; 236:219-42. doi: 10.1111/j.1600-065X.2010.00923.x PMID: 20636820; PubMed Central PMCID: PMC2919275.
41. Patsoukis N, Brown J, Petkova V, Liu F, Li L, Boussiotis VA. Selective effects of PD-1 on Akt and Ras pathways regulate molecular components of the cell cycle and inhibit T cell proliferation. Sci Signal. 2012; 5(230):ra46. doi: 10.1126/scisignal.2002796 PMID: 22740686.
42. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. The New England journal of medicine. 2012; 366 (26):2443-54. Epub 2012/06/05. doi: 10.1056/NEJMoa1200690 PMID: 22658127; PubMed Central PMCID: PMC3544539.